

Supplemental Materials

Figure S1. (Related to Figure 1) Purification of PLpro in bacteria and baculovirus.

- A. Purification of His-TEV-PLpro from bacteria. Lanes 11-13 contain monomer of PLpro from the last step of the purification on a gel filtration column and these were pooled.
- B. Purification of Flag-His-PLpro from baculovirus. Lane 2-4 contain monomer of PLpro from a gel filtration column and were pooled. The tag remains intact with protein.

Figure S2. (Related to Figure 2) Optimization of the FRET assay for PLpro.

- A. PLpro was able to cleave substrate Pro2 (nsp2/3) but not Pro1 (nsp1/2) (see Material & Methods)
- B. PLpro was able to cleave substrate Pro3 (12 amino acids) more efficiently than Pro2 (10 amino acids).
- C. Comparison between the TEV-tagged and Sumo-tagged versions of PLpro enzyme activities.
- D. Comparison between the baculovirus and bacterial (TEV-tagged) purified PLpro.

Figure S3. (Related to Figure 4) Gel-based assay.

- A. Purification of the substrate (67 kDa) with Superdex S200. Fractions 14-18 were pooled and used for the gel-based assay.
- B. Dihydrotanshinone I, beta-lapachone, cryptotanshinone, tanshinone IIA, Cdk4 inhibitor III, GLR-0617, and Ro 08-2750 did not inhibit 3CLpro (nsp5) activity. Z-VAD-FMK is a novel inhibitor discovered against nsp5 (reference nsp5 paper in this issue)

Figure S4. EC₅₀ of beta-lapachone (A), Cdk4 inhibitor III (B), cryptotanshinone (C), and tanshinone IIA (D) from the cell culture-based viral proliferation assay.


Figure S5. (Related to Figure 7) (A and C) Viral proliferation assay for dihydrotanshinone I, Ro 08-2750, GRL-0617, beta-lapachone, cryptotanshinone, tanshinone IIA, and Cdk4 inhibitor III. B. There is no obvious additional effect of

combining remdesivir with compounds in (A). These compounds either do not stop COVID-19 viral proliferation or are cytotoxic.


Table S1. Compound list of over 5000 compounds with scores from low and high concentration.

Table S2. Oligomers and PLpro optimized sequence.


A




B




A




B






C




D



A**B**



A



B

